Study Comparing Acalabrutinib with Other Treatments for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Inclusion Criteria

• Adults aged 18 years or older.
• Good general health with an ECOG performance status of 0 to 2.
• Diagnosed with chronic lymphocytic leukemia (CLL) that meets specific medical criteria.
• Must have CLL with CD20-positive cells.
• Active CLL that requires treatment based on specific medical guidelines, such as worsening anemia, large or growing lymph nodes, or significant symptoms like weight loss or fatigue.
• Must have certain blood counts and organ function levels within specified limits.
• Must have received at least one prior treatment for CLL.
• Women and men who are sexually active must agree to use effective birth control during the study and for a specified time after the last dose of study drugs.
• Willing to participate in all study procedures and able to swallow capsules.
• Able to understand the study and provide informed consent.

Exclusion Criteria

• Known cancer in the central nervous system or certain types of leukemia.
• Uncontrolled autoimmune conditions affecting blood cells.
• Previous treatment with certain cancer drugs like BCL-2 or BCR inhibitors.
• Recent chemotherapy or other cancer treatments within 30 days before starting the study.
• Use of high-dose steroids shortly before starting the study.
• Previous stem cell transplant within 6 months or ongoing complications from it.
• Significant heart disease or recent heart attack.
• Digestive issues that affect medication absorption.
• Recent live virus vaccination.
• Active infections like HIV, hepatitis B, or hepatitis C.
• Serious liver conditions or history of lung inflammation.
• History of severe allergic reactions.
• Recent stroke or bleeding disorders.
• Use of certain medications that affect blood clotting or interact with study drugs.
• Pregnant or breastfeeding women.
• Participation in another clinical trial.
• Certain blood clotting test results outside normal limits.